Source link : https://www.newshealth.biz/health-news/tucatinib-trastuzumab-benefit-remarkable-in-her2-mets-crc/
Only about 3%-5% of patients with metastatic colorectal cancer have tumors that are positive for human epidermal growth factor receptor 2 (HER2), and until recently, there was no treatment approved by the US Food and Drug Administration (FDA) for this subset of patients. That all changed in January of 2023. At that time, the FDA […]
Author : News Health
Publish date : 2024-05-24 08:16:12
Copyright for syndicated content belongs to the linked Source.